Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · abrdn Healthcare Investors (HQH)

H&Q Healthcare Investors renews buyback of up to 12% of shares through July 10, 2014

Neutral Impact 3 of 5 shareholder Written later

H&Q Healthcare Investors, a closed-end fund listed on the NYSE as HQH, said its Board of Trustees renewed its share repurchase program. The renewal lets the fund buy back up to 12% of its outstanding common shares in the open market for a one-year period ending July 10, 2014, replacing the current program that ends July 10, 2013. The Board said the goal is to reduce the discount between the share price and net asset value per share, though the filing gives no assurance of any specific repurchase amount or discount level.

Key points

  • Renewed program allows open-market purchases of up to 12% of outstanding common shares
  • Current program runs through July 10, 2013; renewal extends the period to July 10, 2014
  • Timing and amount of repurchases are at the discretion of Tekla Capital Management LLC, the fund's investment adviser
  • The filing states there is no assurance that repurchases will narrow the discount or raise the share price

The filing

Companyabrdn Healthcare Investors (HQH)
Form8-K, current report
Filed with the SECMar 25, 2013, 1:37 PM ET
Accession number0001104659-13-024055

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 25, 2013.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.